Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.

Miranda S, Choudhari J, Chauhan N, Parmar MS

European journal of pharmacology16 Jul 2025Cited by 7 (Europe PMC)

PMID40675357DOI10.1016/j.ejphar.2025.177953PepBankPUB-40675357

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, pooled randomized trials showed that semaglutide 2.4 mg significantly reduced total cholesterol (mean difference 6.39 mg/dL).
In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide lowered total cholesterol in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
2.4 mg · 68 weeks or moreAs given in this study (human).
Source sentences
Summary
total cholesterol (MD: 6.39 mg/dL, 95 % CI: 9.25 to -3.53, p < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
A systematic search identified four randomized controlled trials evaluating semaglutide 2.4 mg over 68 weeks or more in non-diabetic adults with overweight or obesity.
Report a problemFND-4067535701
02HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, pooled randomized trials showed that semaglutide 2.4 mg significantly reduced LDL-C (mean difference 6.01 mg/dL).
In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide lowered LDL cholesterol in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
2.4 mg · 68 weeks or moreAs given in this study (human).
Source sentences
Summary
LDL-C (MD: 6.01 mg/dL, 95 % CI: 10.17 to -1.85, p < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
A systematic search identified four randomized controlled trials evaluating semaglutide 2.4 mg over 68 weeks or more in non-diabetic adults with overweight or obesity.
Report a problemFND-4067535702
03HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, pooled randomized trials showed that semaglutide 2.4 mg significantly reduced VLDL-C (mean difference 10.67 mg/dL).
In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide lowered VLDL cholesterol in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseVLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
2.4 mg · 68 weeks or moreAs given in this study (human).
Source sentences
Summary
VLDL-C (MD: 10.67 mg/dL, 95 % CI: 17.79 to -3.54, p < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
A systematic search identified four randomized controlled trials evaluating semaglutide 2.4 mg over 68 weeks or more in non-diabetic adults with overweight or obesity.
Report a problemFND-4067535703
04HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, pooled randomized trials showed that semaglutide 2.4 mg significantly reduced triglycerides (mean difference 14.75 mg/dL).
In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide lowered triglycerides in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
2.4 mg · 68 weeks or moreAs given in this study (human).
Source sentences
Summary
triglycerides (MD: 14.75 mg/dL, 95 % CI: 21.30 to -8.19, p < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
A systematic search identified four randomized controlled trials evaluating semaglutide 2.4 mg over 68 weeks or more in non-diabetic adults with overweight or obesity.
Report a problemFND-4067535704
05HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, pooled randomized trials showed that semaglutide 2.4 mg slightly increased HDL-C (mean difference +1.82 mg/dL).
In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide slightly raised HDL cholesterol in pooled trials.
Peptide
Semaglutide
Outcome
IncreaseHDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
2.4 mg · 68 weeks or moreAs given in this study (human).
Source sentences
Summary
slightly increasing HDL-C (MD: +1.82 mg/dL, 95 % CI: 0.90 to 2.74, p < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
A systematic search identified four randomized controlled trials evaluating semaglutide 2.4 mg over 68 weeks or more in non-diabetic adults with overweight or obesity.
Report a problemFND-4067535705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.